Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
TMEM167A pseudogene 2 (TMEM167AP2) is classified as a pseudogene; it is a disabled, nonprotein-coding genomic DNA segment derived from the protein-coding gene TMEM167A[1][4]. Pseudogenes typically do not produce functional protein, and most are not considered molecular drug targets[3]. There is no current evidence that TMEM167A pseudogene 2 has any physiological, pathological, or pharmacological function. Its parent gene, TMEM167A (Transmembrane protein 167A), is involved in vesicle transport and the constitutive secretory pathway in the Golgi apparatus, but the pseudogene does not share these activities[2][6][7]. No drugs, biomarkers, or therapeutic relevance are known or reported for TMEM167A pseudogene 2. According to recognized gene annotation resources, TMEM167AP2 is designated as a pseudogene without known coding or regulatory function[1][4]. Thus, this entity is not a valid therapeutic target and should not be included in curated lists of actionable molecular targets.
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on TMEM167A pseudogene 2 (TMEM167AP2).